The next evolution of the finance function isn’t about controlling cybersecurity spend; it’s about controlling cyber exposure ...

Munich, Germany, April 23, 2026 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company developing small molecule medicines for inflammatory and ...

Tuesday, May 6, 2025 at 8:30 a.m. ET Michael Stein said, "the year over year comparative results for our retail energy ...

There’s a general consensus that too much screen time is bad for kids. But what happens when everything in modern society is ...

The new GLB is a significant step forward over its EQB predecessor, offering seven-seat practicality, cutting-edge technology ...

And last week, MGIC paid a $400 million dividend to the holding company. The dividend from MGIC to the holding company ...

I'd like to welcome you to IBM's First Quarter 2026 Earnings Presentation. I'm Olympia McNerney, and I'm here today with Arvind Krishna, IBM's Chairman, President and Chief Executive Officer; and Jim ...

Single-dose of miv-cel achieved robust and durable improvements in mobility, reversed disability scores, and eliminated the need for chronic ...

ADAPT OCULUS is the first study to evaluate a targeted treatment for ocular MG, demonstrating that VYVGART significantly improves disease ...

Hermès International Société en commandite par actions ( HERM:CA) Shareholder/Analyst Call April 17, 2026 3:30 AM EDT ...

Single-dose of miv-cel achieved robust and durable improvements in mobility, reversed disability scores, and eliminated the need for chronic immunotherapies -- outcomes not previously observed in SPS ...

Late-breaking Phase III FENhance 1 and 2 study results showed superiority of investigational fenebrutinib compared to teriflunomide in reducing relapses and brain lesions in relapsing multiple ...